Samfara completes acquisition of Chr. Olesen Synthesis, Danish manufacturer of controlled-substance APIs

Positive

AI Analysis

Summary

Samfara, a European life sciences investment firm, has completed its acquisition of Chr. Olesen Synthesis, a Danish manufacturer of controlled-substance active pharmaceutical ingredients. The deal marks Samfara's first investment and is backed by a syndicate of European and North American institutional investors and family offices.

Outcome Details

Acquisition completed

Importance:6/10

Sentiment:

0.50

M&AAPI manufacturingcontrolled substancesEuropean investment

Related Companies

$ATALF $TRAX

Read the original article

Published by PR Newswire Biotech on October 2, 2026 6:00 AM

Read Original